Identifying new small molecules for targeted cancer therapy
A Chemoproteomic Approach to Identify Molecular Glues for Targeted Cancer Therapy
This study is looking for new tiny molecules that can help break down certain proteins that cause cancer, especially in patients with acute myeloid leukemia and multiple myeloma, with the hope of finding better treatments that work even when other therapies fail.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11258638 on NIH RePORTER |
What this research studies
This research focuses on developing a novel method to identify small molecules, known as molecular glues, that can help target and degrade specific proteins involved in cancer. By using a chemoproteomic approach, the researchers aim to systematically discover these compounds, which have been difficult to find using traditional methods. The study will explore how these molecular glues can be used to overcome resistance in cancer treatments, particularly in acute myeloid leukemia and multiple myeloma. Patients may benefit from new therapies that more effectively target their cancer cells.
Who could benefit from this research
Good fit: Ideal candidates include patients diagnosed with acute myeloid leukemia or multiple myeloma who have not responded to standard treatments.
Not a fit: Patients with cancers that are not related to acute myeloid leukemia or multiple myeloma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective targeted therapies for patients with difficult-to-treat cancers.
How similar studies have performed: Previous research has shown promise in using molecular glues for targeted cancer therapy, indicating potential for success in this novel approach.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Yoon, Hojong — University of Tx Md Anderson Can Ctr
- Study coordinator: Yoon, Hojong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.